Login to Your Account



Morphotek Gets SPA to Start Phase III Ovarian Cancer Trial

By Jennifer Boggs


Tuesday, March 24, 2009
After yielding promising interim Phase II data, Morphotek Inc.'s farletuzumab is set to enter a pivotal, Phase III trial in ovarian cancer under a special protocol assessment. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription